Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil –tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial
ConclusionsThere are subsets of patients in which one or the other between UFT and CBDCA/PTX is significantly more effective. Selection of adjuvant therapy for NSCLC patients needs to be made taking into consideration the pStage and histological subtype.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Skin Cancer | Squamous Cell Carcinoma | Study